GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.36 (+0.40%)

Growth Price

Overvalued by 32.67%

Stability Price

Overvalued by 70.01%

Company Metrics

  • 33.46 P/E
  • 10.15 P/S
  • 10.34 P/B
  • 2.7 EPS
  • 50.50% Cash ROIC
  • 3.94 Cash Ratio
  • 0 / 0% Dividend
  • 12.34M Avg. Vol.
  • 139.3B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why Gilead Sciences, inc. Stock Was Flat Today
Motley Fool - 4 hours ago
Gilead Sciences (NASDAQ: GILD ) turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter.
Gilead Sciences Beats Expectations, Doubles Its Full-Year Revenue Estimates - Bidness Etc
Why Gilead Sciences, Inc. (GILD) Is Not Rising Despite Blowout Quarter: Meg ... - Tech Insider
3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call
Motley Fool - Jul 22, 2014
I'd like to see Gilead buy an oncology company with a drug or two already on the market. Gilead has idelalisib under review for a couple of a couple different blood cancers and a pipeline of other oncology drugs, but no experience selling cancer drugs.
FDA Okays Gilead Sciences Inc's Zydelig for Blood Cancers
Nature World News - 18 hours ago
The U.S. Food and Drug Administration said Wednesday that it has okayed Gilead Sciences Inc's Zydelig for treatment of three types of blood cancers.
FDA approves Gilead Sciences drug for 3 cancers - Philippine Star
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C ... - Jul 21, 2014
NEW YORK (TheStreet) -- Shares of Gilead Sciences Inc. (GILD_) are up 0.80% to $89.90 in pre-market trade as the company's Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug ...
Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook (subscription) - Jul 23, 2014
Gilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
Gilead: Even This Raging Bull Was Too Pessimistic (GILD)
Seeking Alpha (registration) - 11 hours ago
Biotech Gilead Sciences posted results that crushed estimates after the bell on Wednesday. The company also raised its forward guidance.
Gilead Sciences - Sovaldi Momentum Continues, Appeal Remains (GILD)
Seeking Alpha (registration) - 13 hours ago
This does not mean that Gilead is leaning back. Instead the company announced the accelerated approval of Zydelig by the FDA which is used in combination with Roche's (OTCQX:RHHBY) Rituxan drug to cure three types of blood cancer.
Gilead's Second-Quarter Earnings Expected To Beat Consensus Estimates
Bidness Etc - Jul 22, 2014
Gilead Sciences, Inc. (GILD) will announce earnings for the second quarter of its 2014 fiscal year (2QFY14) on Wednesday.
Understanding The Excitement That Surrounds Gilead
Seeking Alpha (registration) - 6 hours ago
I hope to explain some of the reasons there is so much excitement surrounding this company. Gilead is changing the way we view viral diseases.
Gilead Sciences Director Unloads $448350 in Stock (GILD)
WKRB News - Jul 23, 2014
Gilead Sciences logo Gilead Sciences (NASDAQ:GILD) Director John Francis Cogan unloaded 5,000 shares of the company's stock on the open market in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $89.67, ...